OncoMatch/Clinical Trials/NCT06802718
Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia
Is NCT06802718 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Interferon for acute myeloid leukemia.
Treatment: Interferon — This research focuses on a prospective, randomized, controlled trial of "Interferon-alpha as maintenance therapy for favorable-risk acute myeloid leukemia." By fully utilizing prospective, randomized, controlled clinical trial and studying the negative conversion of MRD and the survival of favorable-risk AML patients, it aims to explore the efficacy and safety of Interferon-alpha in the maintenance treatment of favorable-risk AML and identify effective measures to prevent relapse, thereby improving the survival of favorable-risk AML patients. The primary endpoint is the negative conversion of MRD at 6 months. The secondary endpoints include the 2-year cumulative incidence of relapse, 2-year event-free survival (EFS), 2-year overall survival (OS), and safety.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Excluded: CEBPA bZIP intramolecular mutation
AML with normal karyotype and bZIP intramolecular mutations in CEBPA
Allowed: RUNX1 fusion with RUNX1T1, decreased by > 3 log but still detectable
molecular MRD genes (RUNX1:: RUNX1T1, NPM1, and CBFb:: MYH11) decreased by > 3 log, but still detectable
Allowed: NPM1 mutation, decreased by > 3 log but still detectable
molecular MRD genes (RUNX1:: RUNX1T1, NPM1, and CBFb:: MYH11) decreased by > 3 log, but still detectable
Allowed: CBFB fusion with MYH11, decreased by > 3 log but still detectable
molecular MRD genes (RUNX1:: RUNX1T1, NPM1, and CBFb:: MYH11) decreased by > 3 log, but still detectable
Disease stage
Required: Stage CR1
Excluded: Stage CR2 OR GREATER
Achieved CR1 after 1-2 cycles of standard chemotherapy; At the end of consolidation treatment, bone marrow examination confirmed in CR1
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: standard chemotherapy — induction
Must have received: consolidation chemotherapy (high-dose cytarabine) — consolidation
Lab requirements
Kidney function
creatinine ≤ 1.5 times the upper limit of normal
Liver function
alt and ast ≤ 2.5 times the upper limit of normal, bilirubin ≤ 2 times the upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06802718 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received standard chemotherapy and consolidation chemotherapy.
Are patients with CEBPA alterations eligible?
No. CEBPA bZIP intramolecular mutation is an exclusion criterion.
What disease stage is eligible?
Stage CR1 is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages